NITI Aayog has proposed a ₹50,000 crore BioEconomy Growth Fund and a dedicated Production-Linked Incentive scheme for biomanufacturing to position India as a global biotechnology hub. The roadmap targets scaling India's bioeconomy from approximately $130 billion currently to $300 billion by 2030. Key focus areas include biopharmaceuticals, agri-biotech, industrial biotech, and bio-based materials. The proposal also recommends a National Biomanufacturing Mission and regulatory reforms to fast-track approvals.

India's bioeconomy has grown rapidly — from $10 billion in 2014 to around $130 billion in 2024 — making it one of the top five biotech destinations globally. But NITI Aayog's roadmap identifies a structural gap: India leads in generics and vaccines but lacks deep biomanufacturing capacity, indigenous R&D infrastructure, and risk capital for early-stage biotech firms. The proposed ₹50,000 crore BioEconomy Growth Fund addresses this by blending sovereign funding with private capital, similar in design to the Semiconductor Mission fund. A dedicated PLI for biomanufacturing would extend the logic of PLI schemes — already used for pharmaceuticals and medical devices — to fermentation-based manufacturing, synthetic biology, and bio-based chemicals. This matters for India's economic strategy on multiple fronts: it reduces import dependence in APIs (active pharmaceutical ingredients), supports food security through agri-biotech, and creates high-skilled employment. The National Biomanufacturing Mission would serve as the coordinating architecture, paralleling the National Mission on Quantum Computing. Regulatory streamlining — reducing approval timelines for biosimilars and GMOs — is critical because India's regulatory bottlenecks have historically pushed biotech investment to Singapore and the US. For UPSC, this connects biotechnology policy to Make in India, Atmanirbhar Bharat, GS3 science-and-technology policy, and economic development strategy.